Clinical Trial Update: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating fluzoparib plus adjuvant endocrine therapy for HR+/HER2- SNF3-subtype early breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fluzoparib (fluzoparib)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING